|
Remidio Innovative Solutions, India's leading AI-powered medical imaging company, will showcase its breakthrough eye care technology at the India AI Impact Summit 2026, demonstrating how Indian innovation is preventing blindness at scale and ready to transform global healthcare.
With 16 million people screened across 55+ countries and 1.3 million AI screenings, Remidio has proven that AI can deliver real-world health impact at population scale. In the past year, the company saved 80,000 people from blindness while achieving a 97% reduction in screening costs, from Rs. 2,000 to just Rs. 60 per screening. The company will be prominently featured across multiple high-profile locations at the summit, including the main MeitY Pavilion, the Odisha State Pavilion, and the Andhra Pradesh State Pavilion, as well as the Summit Expo.
Remidio's presence across the MeitY Pavilion and state pavilions demonstrates the confidence that government partners have in the company's technology. This is Indian innovation solving global problems, proven AI that's ready to scale from India to the world.
Remidio's AI has been deployed across five Indian states, Kerala, Pondicherry, Andhra Pradesh, Odisha, and Tamil Nadu, as well as leading healthcare institutions including AIIMS, Apollo Hospitals, LV Prasad Eye Institute, Dr. Mohan's Diabetes Specialities Centre, and Aravind Eye Hospital.
The technology's effectiveness has been validated in the largest real-world AI assessment ever conducted. Published in The Lancet Digital Health and tested by the NHS UK, the study evaluated eight AI systems across 200,000+ patient encounters and 1.2 million retinal images. Remidio was ranked as the most balanced AI system, demonstrating both high accuracy and real-world reliability.
Remidio is the only CDSCO and CE-approved AI system capable of detecting three major causes of blindness, diabetic retinopathy, glaucoma, and age-related macular degeneration, in a single scan. The platform is fully compliant with ABDM, HIPAA, and GDPR standards, making it deployment-ready across India's digital health ecosystem and international markets.
Building on its leadership in AI-driven eye care, Remidio is advancing the frontier of Oculomics, using retinal imaging to identify early risk markers for systemic conditions such as cardiovascular disease, chronic kidney disease, anaemia, neurodegeneration, and maternal health risks. By transforming a simple eye scan into a gateway for whole-person health insights, Remidio is moving from eye care to predictive, preventive healthcare at scale.
The human eye is unlocking early insights into systemic health, and Remidio is at the forefront of this transformation. Remidio is a pioneer in AI-driven eye care, leading the shift from care of the eye to healthcare through the eye. As the first company to receive CDSCO approval in India for our adaptive ophthalmic AI, in addition to CE marking in Europe under Class II EU-MDR, we are redefining how diseases like diabetic retinopathy, glaucoma, and AMD are detected early, in close to patient contexts, while remaining confident of extending this to systemic disease detection such as CVD, CKD and liver diseases, in the future.
|